Tonix Pharmaceuticals Holding Corp. has released preliminary financial results for the quarter ended June 30, 2025. The company reported a net revenue of $2.0 million from the sale of its marketed products, slightly down from $2.2 million in the same period in 2024. The net operating loss significantly decreased to $26.3 million for the quarter, compared to $78.8 million in the previous year. The company's net cash used in operating activities increased to $16.3 million, up from $9.9 million in the same quarter the previous year. Additionally, capital expenditures for the quarter were approximately $1.1 million, compared to $0 in the same period in 2024. Tonix Pharmaceuticals ended the quarter with approximately $125.3 million in cash and cash equivalents. The company expects that its cash resources, along with the $50.6 million raised from equity offerings in the third quarter of 2025, will meet its planned operating and capital expenditure requirements into the third quarter of 2026.